Page 23 - ARNM-3-2

Advances in Radiotherapy
& Nuclear Medicine Role of PET/CT in exploring tumor heterogeneity

under trastuzumab emtansine (T-DM1): The ZEPHIR trial. systemic therapy revealed potential genetic heterogeneity
Ann Oncol. 2016;27:619-624. and poor survival in patients with non‐small cell lung
cancer. Oncologist. 2017;22:61-69.
doi: 10.1093/annonc/mdv577
45. Clark AS, DeMichele A, Mankoff D. HER2 imaging in the doi: 10.1634/theoncologist.2016-0150
ZEPHIR study. Ann Oncol. 2016;27:555-557. 55. Janku F. Tumor heterogeneity in the clinic: Is it a real
doi: 10.1093/annonc/mdw033 problem? Ther Adv Med Oncol. 2014;6:43-51.
46. Chen H, Niu G, Wu H, Chen X. Clinical application of doi: 10.1177/1758834013517414
radiolabeled RGD peptides for PET imaging of integrin 56. Safri F, Nguyen R, Zerehpooshnesfchi S, George J, Qiao L.
αvβ3. Theranostics. 2016;6:78-92. Heterogeneity of hepatocellular carcinoma: From
doi: 10.7150/thno.13242 mechanisms to clinical implications. Cancer Gene Ther.
2024;31:1105-1112.
47. Das SS, Ahlawat S, Thakral P, et al. Potential efficacy of
68 Ga-trivehexin PET/CT and immunohistochemical doi: 10.1038/s41417-024-00764-w
validation of αvβ6 integrin expression in patients with head 57. Morinaga T, Inozume T, Kawazu M, et al. Mixed response to
and neck squamous cell carcinoma and pancreatic ductal cancer immunotherapy is driven by intratumor heterogeneity
adenocarcinoma. Clin Nucl Med. 2024;49:733-740. and differential interlesion immune infiltration. Cancer Res
doi: 10.1097/RLU.0000000000005278 Commun. 2022;2:739-753.
48. Poschenrieder A, Osl T, Schottelius M, et al. First 18F-labeled doi: 10.1158/2767-9764.CRC-22-0050
pentixafor-based imaging agent for PET imaging of CXCR4 58. Sanli Y, Leake J, Odu A, Xi Y, Subramaniam RM. Tumor
expression in vivo. Tomography. 2016;2:85-93. heterogeneity on FDG PET/CT and immunotherapy: An
doi: 10.18383/j.tom.2016.00130 imaging biomarker for predicting treatment response in
patients with metastatic melanoma. AJR Am J Roentgenol.
49. Hicks RJ. Beyond FDG: Novel PET tracers for cancer 2019;212:1318-1326.
imaging. Cancer Imaging. 2003;4:22-24.
doi: 10.2214/AJR.18.19796
doi: 10.1102/1470-7330.2003.0032
59. Mayerhoefer ME, Materka A, Langs G, et al. Introduction to
50. Li Z, Mo C, Li C, Wang Q, et al. Gallium-68 labeled positron radiomics. J Nucl Med. 2020;61:488-495.
emission computed tomography tracer targeting glypican-3
with high contrast for hepatocellular carcinoma imaging. doi: 10.2967/jnumed.118.222893
ACS Pharmacol Transl Sci. 2024;7:4021-4031. 60. Kashyap A, Rapsomaniki MA, Barros V, et al. Quantification
doi: 10.1021/acsptsci.4c00504 of tumor heterogeneity: From data acquisition to metric
generation. Trends Biotechnol. 2022;40:647-676.
51. Kinahan PE, Fletcher JW. Positron emission tomography-
computed tomography standardized uptake values in doi: 10.1016/j.tibtech.2021.11.006
clinical practice and assessing response to therapy. Semin 61. Kocak B, Durmaz ES, Ates E, Kılıckesmez O. Radiomics
Ultrasound CT MR. 2010;31(6):496-505. with artificial intelligence: A practical guide for beginners.
doi: 10.1053/j.sult.2010.10.001 Diagn Interv Radiol. 2019;25:485-495.
52. Zhou J, Li Q, Cao Y. Spatiotemporal heterogeneity across doi: 10.5152/dir.2019.19321
metastases and organ-specific response informs drug 62. Mirshahvalad SA, Eisazadeh R, Shahbazi-Akbari M,
efficacy and patient survival in colorectal cancer. Cancer Res. Pirich C, Beheshti M. Application of artificial intelligence
2021;81:2522-2533. in oncologic molecular PET-imaging: A narrative review
doi: 10.1158/0008-5472.CAN-20-3665 on beyond [ F] F-FDG tracers - Part I. PSMA, choline, and
18
DOTA radiotracers. Semin Nucl Med. 2024;54:171-180.
53. Schmid S, Diem S, Li Q, et al. Organ-specific response to
nivolumab in patients with non-small cell lung cancer doi: 10.1053/j.semnuclmed.2023.08.004
(NSCLC). Cancer Immunol Immunother. 2018;67:1825-1832.
63. Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images are more
doi: 10.1007/s00262-018-2239-4 than pictures, they are data. Radiology. 2016;278:563-77.
54. Dong ZY, Zhai HR, Hou QY, et al. Mixed responses to doi: 10.1148/radiol.2015151169

Volume 3 Issue 2 (2025) 15 doi: 10.36922/ARNM025040005